Latest news with #GammaTile
Yahoo
2 days ago
- Business
- Yahoo
GT Medical Technologies Names James Leech Chief Financial and Strategy Officer
Experienced Life Sciences Executive Joins Leadership Team as Company Further Advances Commercialization of GammaTile® TEMPE, Ariz., June 10, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced that James Leech, a seasoned financial and operational life sciences leader, has joined the company as Chief Financial and Strategy Officer. "We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies," said Per Langoe, CEO of GT Medical Technologies. "I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile®. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption." Mr. Leech will work across the team to accelerate commercial opportunities for GammaTile while spearheading corporate strategy and development, as well as financial and investor management. "I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors," said Mr. Leech. "GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company's continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors." Mr. Leech has considerable experience leading businesses from inception through hyper growth phases of their life cycle. He has advised and worked across the life science industry with direct experience in MedTech, healthcare services, and biopharmaceutical sectors across all major therapeutic areas. Previously, Mr. Leech was the Chief Financial and Strategy Officer of Moximed, a commercial-stage orthopedic device company. Prior to Moximed, Mr. Leech was the Chief Business Officer at Palette Life Sciences from the Company's inception through its acquisition by Teleflex, Inc. Mr. Leech started his career in life science investment banking and strategy consulting. He brings significant cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies across the EU and APAC. GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies
Yahoo
20-05-2025
- Health
- Yahoo
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure TEMPE, Ariz., May 20, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company focused on improving the lives of patients with brain tumors, today announced Allegheny Health Network Neuroscience Institute as the latest GammaTile® Center of Excellence Program designation. The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements. The following physicians are now recognized with achievement: Matthew J. Shepard, MD, Neurosurgeon Rodney Wegner, MD, Radiation Oncologist Stephen Karlovits, MD, Radiation Oncologist Dan Pavord, MS, Physicist Alex Yu, MD, Neurosurgeon Rocco Dabecco, DO, Neurosurgeon Elena Fomchenko, MD, PhD, Neurosurgeon "We are proud to be recognized as a GammaTile Center of Excellence," said Matthew Shepard, MD, Neurological Surgeon at Allegheny General Hospital (AHG), the flagship medical center of Allegheny Health Network (AHN). "GammaTile represents a significant advancement in the treatment of operable brain tumors, giving patients access to effective care when it matters most. At Allegheny General Hospital, we are eager to be at the forefront of innovative brain tumor treatment." GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Health
- Yahoo
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure TEMPE, Ariz., May 14, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company focused on improving the lives of patients with brain tumors, today announced Jersey Shore University Medical Center as the latest GammaTile® Center of Excellence Program designation. The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements. The following physicians are now recognized with achievement: Shabbar F. Danish, MD, FAANS, Professor and Chair, Department of Neurosurgery Nitesh V. Patel, MD, FAANS, Assistant Professor, Department of Neurosurgery, Co-Director of Neurosurgical Oncology Timothy H. Chen, MD, Medical Director, CNS, Department of Radiation Oncology "This designation is a powerful acknowledgment of our commitment to advancing brain tumor care. Innovative treatments like GammaTile are changing what's possible for patients and their families—and we're honored to be part of that progress," Shabbar F. Danish, MD, Chair, Neurosurgery at Jersey Shore University Medical Center. GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
